Kura Oncology Stock Debt To Equity
KURA Stock | USD 20.61 0.10 0.48% |
Kura Oncology fundamentals help investors to digest information that contributes to Kura Oncology's financial success or failures. It also enables traders to predict the movement of Kura Stock. The fundamental analysis module provides a way to measure Kura Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kura Oncology stock.
Last Reported | Projected for Next Year | ||
Debt To Equity | 0.03 | 0.03 |
Kura | Debt To Equity |
Kura Oncology Company Debt To Equity Analysis
Kura Oncology's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Kura Oncology Debt To Equity | 0.01 % |
Most of Kura Oncology's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kura Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Kura Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Kura Oncology is extremely important. It helps to project a fair market value of Kura Stock properly, considering its historical fundamentals such as Debt To Equity. Since Kura Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kura Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kura Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition |
Kura Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Kura Oncology has a Debt To Equity of 0.013%. This is 99.98% lower than that of the Biotechnology sector and 99.93% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.97% higher than that of the company.
Kura Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kura Oncology's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kura Oncology could also be used in its relative valuation, which is a method of valuing Kura Oncology by comparing valuation metrics of similar companies.Kura Oncology is currently under evaluation in debt to equity category among related companies.
Kura Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kura Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kura Oncology's managers, analysts, and investors.Environmental | Governance | Social |
Kura Fundamentals
Return On Equity | -0.37 | ||||
Return On Asset | -0.23 | ||||
Current Valuation | 1.07 B | ||||
Shares Outstanding | 76.18 M | ||||
Shares Owned By Insiders | 1.07 % | ||||
Shares Owned By Institutions | 98.93 % | ||||
Number Of Shares Shorted | 10.35 M | ||||
Price To Earning | (9.03) X | ||||
Price To Book | 3.73 X | ||||
EBITDA | (164.96 M) | ||||
Net Income | (152.63 M) | ||||
Cash And Equivalents | 450.26 M | ||||
Cash Per Share | 6.73 X | ||||
Total Debt | 17.2 M | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 25.73 X | ||||
Book Value Per Share | 6.63 X | ||||
Cash Flow From Operations | (124.82 M) | ||||
Short Ratio | 12.47 X | ||||
Earnings Per Share | (2.17) X | ||||
Target Price | 30.25 | ||||
Number Of Employees | 142 | ||||
Beta | 0.89 | ||||
Market Capitalization | 1.58 B | ||||
Total Asset | 448.94 M | ||||
Retained Earnings | (721.44 M) | ||||
Working Capital | 397.22 M | ||||
Current Asset | 86.87 M | ||||
Current Liabilities | 5.05 M | ||||
Net Asset | 448.94 M |
About Kura Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kura Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kura Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kura Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Kura Oncology Piotroski F Score and Kura Oncology Altman Z Score analysis. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
CEOs Directory Screen CEOs from public companies around the world | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Stocks Directory Find actively traded stocks across global markets |
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.17) | Return On Assets (0.23) | Return On Equity (0.37) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.